JBI-802 is a first-in-class, orally administered, inhibitor of CoREST complex JBI-778 is a potential best-in-class, orally ad...
Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7% Net income of $57.8 million; Adjusted EBITDA of $302.5 milli...
Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing...
Bora Pharmaceuticals Co., Ltd. ("Bora" or "the Company", TWSE: 6472), announced that its Board of Directors has approved the acquisition of US-based ...
AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') announced a new discovery, co-development and license agreement to advance novel targets for ...
Positive data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolle...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported its financial results for the third quarter ended September 28, ...
In a groundbreaking alliance announced, the Florida Lung Health Coalition and DELFI Diagnostics, supported by RadNet, Inc. (NASDAQ: RDNT), and the Ame...
Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, announced it has established a...
Biogen Inc. (Nasdaq: BIIB) – announced the company will present a variety of new data from its felzartamab clinical development program at Kidne...
Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. S...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that Ionis' and AstraZeneca's WAINZUA (eplontersen) has been recommended for approval by the Comm...
Agilent Technologies Inc. (NYSE: A) announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infi...
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, issued the following open lette...
© 2025 Biopharma Boardroom. All Rights Reserved.
